An oral pharmaceutical dosage form comprising n-(2-(2-phthalimidoethoxy) acetyl)-l-alanyl-d-glutamic acid

Abstract

The present invention relates to the pharmaceutical dosage forms which enable a controlled and / or a targeted delivery of an active substance to the selected regions of gastrointestinal tract of humans or animals. More specifically, disclosed is an oral dosage form comprising a core containing the active substance N-(2- (2-phthalimidoethoxy) acetyl)-L- alanyl-D-glutamic acid and a polysaccharide, an inner coat which comprises a polymer selected from the group consisting of methacrylate ester copolymers, mixture of polyvinylacetate and polyvinylpyrrolidone and / or combinations thereof, an outer coat which is insoluble in an acidic environment at pH below 5 which comprises an acidoresistant polymer selected from the group consisting of derivatives of methacrylic acid copolymer, hydroxypropylmethyl cellulose phthalate, hydroxyethycellulose phthalate, cellulose acetate phthalate, polyvinyl acetyl phthalate, hydroxypropylmethylcellulose acetate succinate or combinations thereof.